ANALGESICS FOR CHRONIC PAIN TREATMENT IN THE ELDERLY

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2001
Program:
STTR
Phase:
Phase I
Contract:
PHS2001-2
Agency Tracking Number:
1R41AG018196-01A1
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ST CHARLES PHARMACEUTICALS
478 BROADWAY ST, NEW ORLEANS, LA 70118-3553, NEW ORLEANS, LA, 70118
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
KENNETH NARDUCY
(408) 223-8748
KNARDUCY@MSN.COM
Business Contact:
(504) 861-1664
KNARDUCY@MSN.COM
Research Institution:
LOUISIANA STATE UNIVERSITY

NEW YORK EYE & EAR INFIRMARY
NEW ORLEANS, LA, 70122

Nonprofit college or university
Abstract
DESCRIPTION(adapted from applicant's abstract): Acetaminophen, a nonsteroidal anti-inflammatory drug (NSAID), is widely used for treatment of pain and/or fever in the elderly. This dual action is sometimes contraindicated. In many instances pain needs to be controlled without masking the symptomatic fever (e.g., postoperative period). Acetaminophen can also cause hepatotoxicity, particularly after ingestion of large doses or chronic use of smaller doses (especially in the elderly or when liver function is affected) that can lead to death. Therefore, there is a need for new more selective compounds with greater pharmacological potency and devoid of hepatotoxic or antipyretic effect. We are exploring a series of new proprietary derivatives of acetaminophen. In preliminary studies, one of these compounds (SCP-1) demonstrated high analgesic activity free from antipyretic activity and hepatotoxicity. In this STTR project we propose to further characterize SCP-1 and compare biological properties with acetaminophen. We will also explore combinations of SCP-1 with morphine (and with other pain relievers) to confirm preliminary studies indicating a synergistic effect of this combination. The Phase I experiments will help us ascertain the legitimacy of SCP-1 as a lead candidate drug worthy of further development and testing in Phase II for the treatment of chronic and post-operative pain in the elderly.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government